泽璟制药股东减持与艾伯维合作进展及2026年营收预期

Group 1: Executive Changes - Shareholder ZELIN SHENG plans to reduce holdings by up to 273,907 shares (0.1035% of total share capital) [1] - Shareholder Ningbo Zeao intends to reduce holdings by up to 2,475,090 shares (0.9350% of total share capital) [1] Group 2: Contract Developments - Zai Lab has reached a global development and commercialization agreement with AbbVie for the drug ZG006, granting AbbVie exclusive rights outside Greater China [2] - Zai Lab has received an upfront payment of $100 million and may receive up to $60 million in near-term milestone payments and $1.075 billion in future milestone payments [2] - Clinical trial data for ZG006 shows an objective response rate (ORR) of 53.3% and a median progression-free survival (mPFS) of 7.03 months in the II phase dose optimization trial for small cell lung cancer and neuroendocrine cancer [2] Group 3: Product Development Progress - The injectable ZG005 has confirmed an ORR of 40.9% and a disease control rate (DCR) of 68.2% in II phase clinical trials for cervical cancer [3] - Several candidate drugs, including ZGGS18 and ZGGS34, have entered phase I clinical trials in China and the U.S. [3] Group 4: Financial Performance - The company expects revenue for 2026 to be between 796 million and 829 million yuan, representing a year-on-year growth of 49.45% to 55.55% [4] - This growth is primarily driven by the increase in sales of recombinant human thrombin and the commercialization of Jikaxitinib [4]